REMOZEN MV 1000 TABLET is a combination of Metformin, Remogliflozin and Vildagliptin which belongs to the group of medicines called Antidiabetic agents. It is used to improve glycaemic control among patients with Type II diabetes mellitus when diet, exercise and other conventional managements does not provide adequate control on blood glucose levels.

Take REMOZEN MV 1000 TABLET strictly as instructed by your doctor. Do not stop using this medicine abruptly without consulting your doctor.

While taking REMOZEN MV 1000 TABLET, always carry a sugary snack with you and consume it immediately when experience any signs of hypoglycemia (such as tiredness, fatigue, hunger, irritability, lack of concentration, etc.).

Before taking REMOZEN MV 1000 TABLET inform your doctor if you have any liver, kidney or heart problems. You must also inform your doctor if you have low blood pressure, breathing problems, type I diabetes, urinary tract infections or scheduled for an X-ray as a precaution.

During therapy with REMOZEN MV 1000 TABLET, your doctor might regularly monitor your blood sugar levels, liver functions and kidney functions to avoid the risk of unwanted side effects. He/she might also ask you to make certain lifestyle changes such as following a healthy diet, regular physical exercise and quitting alcohol consumption to achieve better results. Follow proper foot care and regularly check your foot for any exacerbations or ulcers.

REMOZEN MV 1000 TABLET is not recommended for use in patients with severe uncontrollable diabetes. It is also not suitable for use in patients with alcoholism and severe systemic infections.

The most common side effects of taking [GBKEYWORD] are low blood sugar levels, nausea, flatulence, constipation, stomach pain, dizziness, changes in taste, a sore and red tongue, urinary tract infection, fever, low blood pressure, passing no urine or more urine, thirst, increased urination at night, anemia, weight loss and joint pain. However, if these side effect bothers you or worsens contact your doctor.